Bioray Laboratories
Clinical trials sponsored by Bioray Laboratories, explained in plain language.
-
Engineered immune cells take on Hard-to-Treat blood cancer
Disease control Recruiting nowThis early study tests a new treatment called BCMA-UCART for adults with multiple myeloma that has come back or not responded to other therapies. The treatment uses donor immune cells that are specially designed to find and attack cancer cells. The goal is to see if it is safe an…
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Off-the-shelf cell therapy takes on lymphoma
Disease control Recruiting nowThis early study tests a new type of cell therapy called universal CAR-T cells in people with relapsed or treatment-resistant B-cell non-Hodgkin lymphoma. The therapy targets a protein called CD19 on cancer cells. Up to 6 adults will receive the treatment to check safety and how …
Phase: NA • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T cell therapy (BRL-201) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target cancer cells and designed to be safer by …
Phase: PHASE1 • Sponsor: Bioray Laboratories • Aim: Disease control
Last updated May 11, 2026 20:47 UTC